SARS-CoV-2 (2019-nCoV) Spike ELISA Kit

Product Name: SARS-CoV-2 (2019-nCoV) Spike ELISA Kit.
Assay Type: Solid Phase Sandwich ELISA (quantitative).
Conjugate: HRP
Specificity: Recognizes both recombinant and natural 2019-nCoV CoV spike.
Regulatory/Restrictions: For Research Use Only

Materials Supplied:

– 96 well microplate coated with Capture Antibody
– Detection Antibody conjugated to HRP
– Standards
– Wash Buffer Concentrate
– Dilution Buffer Concentrate
– Color Reagent A
– Color Reagent B
– Stop Solution

Shipping:

Ambient temperature

Storage:

Unopened Kit: Store at +2 – 8°C
Opened/Reconstituted Reagents: Please refer to CoA.

SARS-CoV-2 (2019-nCoV) Spike ELISA Kit Datasheet

Corona Virus Disease 2019 (COVID-19) is caused by the SARS-associated coronavirus 2 (SARS-CoV-2), which was first identified in a respiratory disease outbreak in Wuhan City, Hubei Province, China. It has since been responsible for a global pandemic. SARS-CoV-2 is a single-stranded RNA virus with positive polarity and belongs to the genus of beta-coronaviruses, which also includes SARS CoV (2003) and MERS CoV (2012). Like all other corona viruses, the genome of SARS CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein and the nucleocapsid protein.

ELISA kits for COVID-19 diagnostics

COVID-19 positive patients display a variety of symptoms with a large range of severity. Current research guidance suggests the length of time from initial infection with SARS-CoV-2 and appearance of first symptoms can be up to 14 days. RT-qPCR tests performed in hospital to confirm diagnosis in acute patients. This type of test examines the genetic material of the virus and give a positive result only if the virus is still present at a critical level. The tests are unable to identify individuals who have recovered. The GA CoV-2 ELISA kits are serological tests that identify virus-specific antibodies in patients both during and post infection. Understanding the level of population exposure to SARS-CoV-2 and the number of recovered patients is key to a resilient pandemic response. Our simple GA CoV-2 Two Step ELISA confirms active cases and can indicate the level of immune protection following recovery by specifically identifying the IgG response to N-, S1- and S2- proteins are determined using GA CoV-2 IgG+ EIA  confirmatory test.